Kornimate/medical-research-clean huggingface dataset:
modulation of muscle protein synthesis with diet and exercise in old aged women

Conditions: Sarcopenia

Summary: in this study will measure differences in how muscle responds to both exercise and protein supplements in healthy women aged 60-69. we are studying two different protein supplements- a standard whey protein and a leucine enriched supplement. each patient would receive either one of these.

one of the factors that plays an important role in the loss of functional performance and, as such, the capacity to maintain a healthy, active lifestyle is the progressive loss of skeletal muscle mass with ageing (i.e., sarcopenia). indeed, sarcopenia is a more robust predictor of functional status and mortality in the elderly than chronological age or indeed, any other co-morbidity. sarcopenia is an incipient process whereby lean muscle mass contributing up to \~50% of total body weight in young adults declines to \~25% when reaching the age of 75-80 y. adequate nutritional intake, and in particular dietary protein, is important for offsetting age-related declines in muscle mass. the aim of this project is to seek the most effective nutrition with which to counteract sarcopenia, specifically in women.

Eligibility criteria:
inclusion criteria: * healthy post-menopausal females aged 60-70 exclusion criteria: * • obvious muscle wasting. * a body mass index (bmi) \ 40 kg•m2. * active cardiovascular disease: uncontrolled high blood pressure, angina, heart failure (class iii/iv), abnormal heart rhythm, right to left cardiac shunt or recent cardiac event. * taking statin-based medication above 60mg•day-1. * individuals taking beta-adrenergic blocking agents or non-steroidal anti-inflammatory agents (nsaids) * cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial). * respiratory disease including pulmonary hypertension, chronic obstructive pulmonary disease (copd), asthma or a forced expiratory volume (fev1) less than 1.5 litres. * metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, cushing's disease, types 1 or 2 diabetes. * active inflammatory bowel disease, renal disease, or malignancy. * recent steroid treatment (within 6 months), or hormone replacement therapy. * clotting dysfunction e.g. deep vein thrombosis, pulmonary embolus, warfarin therapy and/ or haemophilia. * musculoskeletal or neurological disorders. * any leg amputated * family history of early (\<55y) death from cardiovascular disease. * known sensitivity to sonovue (us contrast).

Keywords: muscle protein synthesis muscle protein breakdown
aquacel® ag+ extra™ and cutimed™ sorbact® dressing in the management of venous leg ulcers over a 12-week period

Conditions: Venous Leg Ulcer; Diabetic Foot

Summary: study is to provide evidence comparing aquacel® ag+ extra™ versus cutimed® sorbact® in the progression of wounds towards healing

post market, multi-centre, randomised, open label, multi-national, prospective study to provide evidence comparing aquacel® ag+ extra™ versus cutimed® sorbact® in the progression of wounds towards healing

Eligibility criteria:
inclusion criteria: * venous insufficiency as defined by ceap classification of c6 * one wound amendable to treatment with either aquacel® ag+ extra™ or cutimed® sorbact® * wounds that have been present for at least 2 months * reliable and available for follow-up * 18 years or older * able and willing to provide informed consent * able to tolerate compression therapy for venus leg ulcer * must be able to be compliant with compression therapy exclusion criteria: * known sensitivities or allergies to components of the aquacel® ag+ extra™ or cutimed® sorbact® * continued use of petroleum gel/ creams/ oil-based products * active treatment for cancer or completed within the last 3 months * documented severe malnutrition * malignant wounds * systemic infection actively treated with antibiotics
cuida-te, an app for the emotional management

Conditions: Emotional Distress; Burnout, Professional; Emotional Stress

Summary: the aim of this study is to develop and validate an ecological momentary intervention app for healthcare workers, in order to face of work-related stresses generated by the covid-19 pandemic.

the covid-19 pandemic has had a very high emotional impact on healthcare workers. ecological momentary interventions (emi) can offer an intervention in real time, when the emotion arises. cuida-te is an emi app based on principles of different transdiagnostic cognitive behavioral interventions focused on emotion regulation. the effectiveness of cuida-te will be investigated in the current study. a two-arms randomized controlled trial (rct) will be conducted. at least 182 healthcare workers will be randomly assigned to a 2-month immediate intervention group (cuida-te app, n= 91), or a control group (no assessment or intervention, n=91). the cuida-te consists of an app-based emi that estimates and intervenes based on ecological momentary assessment data of five emotional states: joy, fatigue, sadness, anxiety, anger, as well as sleep quality, sleep quantity, burnout, perceived stress, and self-perception of coping skills. the primary outcome is the phq-9. secondary outcomes include erq, ders, oasis, brs, sus, and proqol questionnaires. primary and secondary outcomes will be obtained at pre- and post-intervention measurements, and at 3-month follow-up measurement.

Eligibility criteria:
inclusion criteria: * to be a healthcare worker in active (from 18 until 67 years) * to have a smartphone with internet access and android operating system. exclusion criteria: * to be in psychological treatment at the time of the recruitment
development and validation of models to predict postoperative complications for patients with cardiac surgery

Conditions: Surgery--Complications

Summary: patients undergoing cardiac surgery is routinely performed in clinical scenarios, highly postoperative morbidities and long-term mortality should be modified. a simple risk prediction model incorporating risk factors can help guide clinical decision making, patient counseling and treatment planning.

patients undergoing cardiac surgery is routinely performed in clinical scenarios, highly postoperative morbidities and long-term mortality should be modified.a nomogram is a pictorial representation of a scoring model that possesses a simple user interface and shows favorable predictive performance. by integrating a patient's diverse determinant variables, a nomogram can provide a personalized probability for quantitative predictions of the incidence of an outcome of interest.therefore, we conducted a retrospective study to assess the incidence, risk factors and outcomes associated with major complications patients undergoing cardiac surgery.

Eligibility criteria:
inclusion criteria: age more than 18 years undergoing cardiovascular surgery exclusion criteria: missing primary outcomes or variables
evaluating the potential usefulness of 18f-alf-fapi pet/ct in patients with gastrointestinal tumors and compared with 18f-fdg pet/ct

Conditions: Gastric Cancer; Pancreatic Cancer; Liver Cancer

Summary: to evaluate the potential usefulness of 18f-alf-fapi positron emission tomography/computed tomography (pet/ct) for the diagnosis of primary and metastatic lesions in gastrointestinal tumors, and compared with 18f-fdg pet/ct.

subjects with gastrointestinal tumors underwent contemporaneous 18f-alf-fapi and 18f-fdg pet/ct either for an initial assessment or for recurrence detection. tumor uptake was quantified by the maximum standard uptake value (suvmax). the numbers of positive tumor lesions of 18f-fdg and 18f-alf-fapi pet/ct were recorded by visual interpretation. the sensitivity, specificity, and accuracy of 18f-alf-fapi, 18f-fdg pet/ct were calculated and compared to evaluate the diagnostic accuracy.

Eligibility criteria:
inclusion criteria: * adult patients (aged 18 years or order); * patients with suspected or newly diagnosed or previously treated gastrointestinal tumors (supporting evidence may include mri, ct, tumor markers and pathology report); * patients who had scheduled both 18f-fdg and 18f-alf-fapi pet/ct scans; * patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the clinical research ethics committee. exclusion criteria: * patients with non-malignant lesions; * patients with pregnancy; * the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Keywords: diagnosis positron-emission tomography gastric cancer pancreatic cancer liver cancer
anal manometry examination in patients with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: inflammatory bowel diseases (ibd), which include crohn's disease (cd) and ulcerative colitis (uc), are chronic immune-related diseases. ibd symptoms frequently overlap with symptoms of functional gi disorders such as irritable bowel syndrome (ibs) and defecatory disorders, and these symptoms are common in patients with active disease, and also in quiescent disease. underdiagnosis of abnormal anorectal function may result in an inappropriate escalation of ibd therapy. in this study, the investigators aim to evaluate if damage from chronic inflammation in uc results in anorectal damage such as hypersensitive, hyperactive, poorly compliant rectum, and hypotensive sphincter. if this is the case, early aggressive treatment of the disease is needed. another important point in this study is to find out which of the anorectal symptoms are due to a hypersensitive, hyperactive, and poorly compliant rectum and not due to mucosal inflammation. the diagnosis of abnormal anorectal function via manometry may help to give the appropriate treatment, such as biofeedback or pharmacological treatment such as loperamide or tricyclic anti-depressants. this may avoid escalation or replacing effective ibd therapy unnecessarily.

the study will include patients with ulcerative colitis in clinical, laboratory, and endoscopic remission, and with one of the following symptoms: urgency, fecal incontinence, incontinence to gas, tenesmus, rectal discomfort, rectal pain, excessive straining and incomplete evacuation. patients that will not be included: patients after ileal pouch-anal anastomosis (ipaa), and patients with colonic stenosis that could not be passed with an endoscope. patients will undergo an anorectal manometry test and the results will be compared to a control group that will include patients with ulcerative colitis in remission without anorectal complaints, as well as to the normal values in the literature.

Eligibility criteria:
inclusion criteria: * patients with uc in our clinics who have one of the following symptoms: urgency, fecal incontinence, incontinence to gas, tenesmus, rectal discomfort, rectal pain, excessive straining, and incomplete evacuation * a patient who has had a recent colonoscopy/sigmoidoscopy with endoscopic remission defined as mayo endoscopic score ≤1 exclusion criteria: * patient after ileal pouch-anal anastomosis surgery (ipaa) * patients with colonic stenosis that did not allow endoscopic passage and did not undergo an endoscopic evaluation prior to the study
automated adjustment of oxygen on patient with acute copd exacerbation - freeo2 hyphop

Conditions: Oxygen Toxicity; COPD Exacerbation; Hyperoxia; Hypoxemia; Hypoxic Respiratory Failure

Summary: the aim of this study is to evaluate if automated adjustment of oxygen (with freeo2 device) can reduce the hospital length of stay for acute exacerbation of copd with comparison of manual oxygen titration.

the aim of this study is to evaluate if automated adjustment of oxygen (with freeo2 device) can reduce the hospital length of stay for acute exacerbation of copd with comparison of manual oxygen titration. patients with severe acute exacerbation of copd requiring hospitalization will be included in this randomized controlled study and will be managed with either manual oxygen titration or automated oxygen titration (freeo2 arm). the impact on the hospital length of stay will be evaluated.

Eligibility criteria:
inclusion criteria: * copd or suspected copd ( age\>40, active or smoking history \> 10pack/years), - * acute exacerbation (increasing dyspnea recently) * one or more of the following criteria: increased sputum, modification of sputum purulence,increased dyspnea, * moderate oxygen therapy: oxygen flow \ or = 92% (for long term oxygen therapy, the oxygen flow must be greater than baseline flow to maintain spo2 \> or = 92%) exclusion criteria: * patient refusal * copd exacerbation with diagnosis highly related to pulmonary embolism, cardiac pulmonary edema, pneumothorax or sedative overdose * no spo2 signal * encephalopathy score \> 2 * delirium * other respiratory support needed (intubation or niv) * patient on withdrawal life support * advance neoplasia (palliative stage) or terminal respiratory distress * unavailability of freeo2 device at the randomisation * non optimal patient collaboration
postoperative pain intensity associated with the use of different nickel titanium instrumentation systems

Conditions: Pain, Postoperative; Endodontically Treated Teeth

Summary: in this study the effect of different engine-driven nickel titanium (ni-ti) instrumentation systems (oneshape, revo s and waveone) on postoperative dental pain in patients with asymptomatic teeth after a single-appointment root canal retreatment was evaluated.

the aim of this clinical study was to evaluate the effect of different engine-driven nickel titanium (ni-ti) instrumentation systems (oneshape, revo s and waveone) on postoperative dental pain in patients with asymptomatic teeth after a single-appointment root canal retreatment. a total of a hundred thirty nine patients with asymptomatic teeth and with no contradictory medical history who were indicated for non-surgical retreatment at the endodontic clinic, faculty of dentistry, istanbul medipol university, between september and december 2016 were included in this study. all of the patients have been recruited from the istanbul medipol university dental clinics in istanbul. out of a hundred thirty nine patients, a total of ninety-nine patients who met the inclusion criteria and agreed to participate was enrolled for the study and were divided into three groups (n=33). consent was obtained from all study participants before the treatment. after removing previous root canal filling, instrumentation was performed using one shape, revo-s, and waveone in groups 1, 2, and 3, respectively. all retreatments were performed in a single appointment by one endodontist before permanent coronal restoration. postoperative pain intensity was assessed at 6, 12, 18, 24, 48, and 72 h; 7 days; and 1 month after the retreatment. the teeth was examined according to for pain intensity, percussion \& palpation sensitivity, swelling, analgesic intake and clinical status.

Eligibility criteria:
inclusion criteria: * asymptomatic teeth * patients with no contradictory medical history * patients who were indicated for non-surgical retreatment and * patients who were above 18 years old exclusion criteria: * patients aged below 18 years; * symptomatic teeth, * teeth with vertical root fractures * teeth with excessive periodontal disease; * patients who received or required surgical endodontic treatment * patients diagnosed with systemic diseases * patients who used analgesics 12 h before or * patients who used antibiotics 1 month before the retreatment

Keywords: endodontic retreatment postoperative pain oneshape revo-s waveone
adipose tissue response to overfeeding in insulin resistance-prone vs. insulin sensitive humans

Conditions: Insulin Resistance; Obesity

Summary: obesity has become an epidemic worldwide. data from our laboratory and others demonstrate that most of the excess morbidity from obesity is related to insulin resistance (ir). while total adiposity correlates with insulin resistance, not all obese individuals are ir. when obese ir individuals lose weight in response to caloric restriction, even moderate loss of body fat results in improved insulin sensitivity (is). with massive weight loss, either dietary or surgical, even the most ir individuals can completely reverse their insulin resistance. but why is one individual ir at a bmi of 26 and another is at a bmi of 35? there must be differences in the manner in which adipose cells/tissue respond to caloric excess and weight gain. one potentially unifying hypothesis with regard to obesity-associated insulin resistance is that those individuals who fail to respond to caloric excess/obesity with adequate adipocyte differentiation and expanded subcutaneous fat storage capacity develop increased circulating ffas, ectopic fat deposition, stress on adipocytes, triggering localized and systemic inflammation and ultimately insulin resistance in skeletal muscle. clearly, the best way to examine the human response to obesity is to challenge overweight individuals with the need to store excess triglyceride in adipose tissue. specific aims are: 1. test the hypothesis that impaired adipogenesis and fat storage capacity are associated with insulin resistance by comparing 1) cell size distribution; 2) gene markers of adipose cell differentiation; 3) differentiation of isolated preadipocytes in ir-prone vs is individuals subjected to caloric excess. 2. determine if circulating (daylong ffa, two-stage insulin suppression test) and ectopic fat (mri liver, ct abdomen) are worsened to a greater degree in ir-prone vs is individuals subjected to caloric excess. 3. determine whether differences in inflammation and/or innate or adaptive immune response are associated with insulin resistance by comparing differences in resident dendritic cells, macrophages and their activation profiles, changes in t-cell subpopulations, and other inflammatory mediators in ir-prone vs is individuals who are subjected to caloric excess via overfeeding. 4. exploratory: evaluate ir-prone vs is individuals for evidence of hypoxia and insufficient angiogenic response in response to caloric excess.


Eligibility criteria:
inclusion criteria: * bmi 25-35 kg/m2 * healthy adults * age 35-65 * weight stable * nondiabetic exclusion criteria: * major organ disease such as heart, kidney, liver * malignancy * inflammatory conditions (eg. lupus, rheumatoid arthritis, crohn's disease) * eating disorder h/o bariatric surgery or liposuction use of blood thinners such as coumadin (aspirin is ok)

Keywords: ectopic fat obesity triglyceride storage adipocyte overfeeding intrahepatic fat adipocyte proliferation inflammation macrophage
the role of egfr mutations in pancreatic cancer patients receiving gemcitabine with or without erlotinib

Conditions: Metastatic Pancreatic Cancer

Summary: the purpose of this study is to investigate the influence of epidermal growth factor receptor mutations on the efficacy of erlotinib and gemcitabine in metastatic pancreatic cancer.

the influence of egfr mutations on the efficacy of treatment with and without erlotinib in metastatic pancreatic cancer is to be determined.

Eligibility criteria:
inclusion criteria: * metastatic chemotherapy-naïve pancreatic cancer patients * histologically confirmed * adequate samples for analysis * eastern cooperative oncology group (ecog) performance status \<= 2 * absolute neutrophil count (anc) \>= 1,500/mm3 * platelet count \>= 100,000/mm3 * serum creatinine \<= 1.5 mg/dl * aspartate aminotransferase (ast) * alanine aminotransferase (alt) \< 5 times the upper limit of normal exclusion criteria: * absence of any other malignancy or serious medical or psychological illness that would preclude informed consent
observational study on blood glucose control in patients with diabetes using modern insulin

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: the study is conducted in europe. the aim of this observational study is to evaluate the blood glucose control in patients using a modern insulin: novorapid®, novomix® 30 or levemir® for the treatment type 2 diabetes. full acronym for this study: commit - clean switch


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes * patients treated with human soluble insulin, nph insulin or premixed human insulin * patients willing to sign informed consent * selection of study participants at the discretion of the physician exclusion criteria: * subjects currently being treated with insulin aspart, insulin detemir or biphasic insulin aspart 30 * subjects who were previously enrolled in this study * subjects with a hypersensitivity to insulin aspart, insulin detemir or biphasic insulin aspart 30 or to any of the excipients
the effect of an additional bolus application in patients with intrathecal opiate administration - a pilot study

Conditions: Chronic Pain Syndrome

Summary: an additional, intermittent bolus application in patients with intrathecal opiate administration for chronic pain syndrome may have a positive effect on the effectiveness of the treatment. thus, the effect of an additional, intermittent bolus application in patients with intrathecal opiate administration was therefore investigated. patients already equipped with an intrathecal opiate pump were enrolled into the study. each patient was submitted to two treatment periods in randomly chosen order (cross-over design): 1. standard treatment (continuous opiate administration) and 2. continuous opiate administration with intermittent opiate bolus application. both treatment periods lasted 14 days. patients were asked to record pain intensity, side effects and satisfaction with the treatment. the following hypotheses were tested: * the application of additional opiate boli results in significantly lower pain intensity. * the application of additional opiate boli does not result in a higher rate of adverse events.


Eligibility criteria:
inclusion criteria: * chronic pain syndrome * intrathecal opiate pump * signed informed consent exclusion criteria: * younger than 18 years * other (than opiate) intrathecal drug administration * discontent with intrathecal opiate therapy
a clinical study conducted in multiple centers evaluating escalating doses of veliparib in combination with capecitabine and radiation in patients with locally advanced rectal cancer

Conditions: Locally Advanced Rectal Cancer

Summary: an open-label, phase 1b, dose escalation study evaluating the safety and tolerability of the parp inhibitor veliparib in combination with capecitabine and radiation in subjects with locally advanced rectal cancer (larc).


Eligibility criteria:
inclusion criteria: * subject must be ≥ 18 years of age * all subjects must have newly diagnosed, histologically proven adenocarcinoma of the rectum * all subjects must have an abdominal/pelvis computed tomography (ct ) scan or magnetic resonance imaging (mri) confirming no evidence of distant metastases * distal border of tumor \< 12 cm from anal verge * subjects must have an eastern cooperative oncology group (ecog) performance score of 0 to 2 * no prior treatment for larc however prior treatments for other cancers are acceptable as long as they are considered curative exclusion criteria: * subject is an unsuitable candidate for tme surgery * subject has received anticancer therapy * subject has received prior radiation therapy * subject has had major surgery within 28 days prior to the first dose of study drug * history of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, ph or absorption

Keywords: dlt radiation veliparib locally advanced rectal cancer abt-888 capecitabine mtd parp